The analysis of CSF molecular markers, including the core AD biomarkers amyloid‐β 42, phosphorylated tau and total tau, has proved effective for the differential diagnosis of iNPH from cognitive, movement and cerebrovascular mimic disorders (Jeppsson et al., 2019; Manniche, Hejl, Hasselbalch, & Simonsen, 2019). The gene discussed is MAPT; the disease is Alzheimer disease.